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ABSTRACT  
Technological developments in gene editing raise high expectations for clinical applications, 
first of all somatic gene editing but in theory also germline gene editing. The latter is 
currently not allowed in many countries. This makes clinical applications in these countries 
impossible now, even if germline gene editing would become safe and effective. What were 
the arguments behind this legislation, and are they still convincing? If a technique can help to 
avoid serious genetic disorders, in a safe and effective way, would this be a reason to 
reconsider earlier standpoints? The European Society of Human Reproduction and 
Embryology (ESHRE) and European Society of Human Genetics (ESHG) together developed a 
Background Document and Recommendations to inform and stimulate ongoing societal 
debates. After consulting its membership and experts, this final version of the 
Recommendations was endorsed by the Board and Executive Committee of the Societies in 
May 2017. Taking account of ethical arguments, we argue that both basic and preclinical 
research regarding human germline gene editing can be justified on conditions. Furthermore, 
while clinical germline gene editing would be totally premature, it might become a 
responsible intervention in the future, but only after adequate preclinical research. Safety of 
the child and future generations is a major concern. Future discussions must also address 
priorities among reproductive  and potential non-reproductive alternatives, such as 
preimplantation genetic diagnosis and somatic editing if that would be safe and successful. 
The prohibition of human germline modification however needs renewed discussion among 
relevant stakeholders, including the general public and legislators.  
    
Keywords: germline gene editing; professional policy; recommendations; ethics; responsible 
innovation  
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Introduction 
Recent research and expected further studies in gene editing raise high expectations, especially 
regarding possible therapeutic applications in humans. Most promising is the prospect of somatic 
gene editing, which may prove to be a game changer not only in the treatment of a whole range of 
serious genetic disorders, especially Mendelian ones, but also in the treatment of cancer and 
infectious diseases. Over 5000 Mendelian diseases are identified whereas currently treatment is 
available for only a small minority of these. At the same time, the possibility of a future application in 
the human germ-line raises serious concerns. In previous decades, legislation has been adopted that 
does not allow changes to the human germline. What were the arguments behind this legislation, do 
they still apply and are they still convincing? If a technique can help to avoid serious genetic disorders 
(with severe effects on quality of life or life span) in a safe and effective way, would this be a reason 
to reconsider earlier standpoints? Discussion with relevant stakeholders is needed, including 
professional health care workers, patients and different lay publics, legal and ethical experts. 
Recently, initiatives have been taken worldwide to exchange views and re-ignite the debate about 
responsible governance and approaches to innovation using human gene editing. The European 
Society of Human Genetics (ESHG) and the European Society of Human Reproduction and 
Embryology (ESHRE) consider it to be their professional responsibility to contribute to further 
discussion by means of a set of Recommendations, based on a Background paper, focusing on human 
germline gene editing (GLGE). 
The aim of this contribution is to inform and stimulate ongoing societal debates, as well as provide 
guidance, taking into account: the technical aspects of GLGE, its different possible applications, 
relevant clinical experience regarding the handling of reproductive risk, legal regulations, and the 
ethical and societal issues and concerns linked with GLGE. Because of the importance of the latter, 
both the ESHG and the ESHRE invited their relevant committees (respectively the Public and 
Professional Policy Committee of the ESHG and the Ethics Committee of the ESHRE) to take the lead 
in writing the Background paper and Recommendations. Drafts were prepared by a joint writing 
group.  These were discussed in both committees and in a joint meeting of the two societies on 
September 20, 2016. Next, a draft of the Recommendations was posted online from October 17 until 
December 2, 2016 and was presented at the ASHG meeting in Vancouver. The Background document 
and the Recommendations have been posted online to solicit comments from the membership of 
both ESHG and ESHRE from April 3 until  May 8, 2017. After integrating the comments, the 
Recommendations have been endorsed by the Board of ESHG and the Executive Committee of ESHRE 
in May 2017. This Document has a provisional nature, and is to be re-evaluated regularly, taking 
account of relevant scientific developments, possible future clinical experiences, and evolving 
societal discussions and ethical reflection. The Recommendations should be understood against the 
argumentation provided in the Background document. We strongly recommend also reading this 
Background document and will refer to relevant sections below. 
 
Recommendations 
In preparing this Document, it was considered crucial to make a distinction between non-
reproductive GLGE in basic research, non-reproductive GLGE in preclinical research and possible 
future clinical (reproductive) GLGE.  
Opmerking [CM1]: Expected May 2017 
 
This text will be the final version 
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I. Non-reproductive germ-line gene editing in basic research 
Non-reproductive GLGE primarily concerns the context of basic research. Although a sharp 
demarcation between basic research and preclinical research is difficult to make, basic research in 
this context is characterized by a focus on fundamental questions regarding human embryology and 
the methods applied in gene editing. Reproductive treatments in health care and adequate patient 
counseling may be served by a better knowledge of early embryo development. There are good 
reasons to allow basic research in this area, subject of course to societal oversight and taking account 
of relevant ethical guidelines and (inter-)national legal regulations. 
The research use of human somatic cells and (precursor cells of) gametes is less controversial 
than human embryo research in vitro. The Oviedo Convention categorically prohibits the making of 
human embryos specifically for research purposes (‘research embryos’).  Several European countries 
rely on the use of spare embryos left over after IVF procedures only. If necessary  and possible the 
use of spare embryos over embryos created for research should be the preferred option. However, 
also from an ethical point of view, a prohibition to make such embryos may be contested. As 
elaborated in the Background document, the making of research embryos could be morally justified, 
subject to ethical, legal and societal oversight, if the research question cannot be adequately 
addressed on the basis of spare embryos only and if research embryos are necessary to reach the 
aim(s) of scientifically sound and robust research.  Given the sensitivity of human germ-line 
interventions, the specific consent of the providers of the gametes and embryos to such basic 
research use should be obtained.  
 
II. Non-reproductive germ-line gene editing in preclinical research 
Only after acquiring robust knowledge from basic research, might future clinical applications be 
considered, which would require further societal and professional discussions. Both for scientific and 
moral reasons, as a precondition for any potential clinical applications of GLGE, adequate preclinical 
GLGE is necessary. Preclinical research, involving both animal research and human embryo research, 
is an important element of the moral framework for the introduction of new, experimental, 
reproductive technologies generally. Given the specific sensitivity of GLGE, such research would have 
to take place under ongoing monitoring and societal oversight. Pre-clinical GLGE research would 
involve investigation of the safety (e.g. possible off-target effects or epigenetic effects) and 
effectiveness of gene editing in view of possible future reproductive applications of GLGE in gametes, 
zygotes or preimplantation embryos. Such research is important to identify and eliminate, or at least 
reduce, avoidable risks for any future children thus conceived.  
Conceptually, the term preclinical research alludes to potential clinical applications at least being 
considered, if not intended. However, preclinical research is a necessary, but not sufficient 
prerequisite for future applications, and such applications do certainly not automatically follow from 
allowing preclinical research as is outlined in the Background Document.   
‘Comprehensive’ genetic testing of embryos (Preimplantation Genetic Testing, PGT) using whole 
genome sequencing might be an integral part of adequate pre-clinical research on the safety and 
specificity of GLGE to investigate potential off-target effects. The issue of how to handle possible 
incidental findings regarding the genetic make-up of the providers of the gametes or embryos should 
be addressed in the informed consent process, taking account of relevant guidelines. 
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According to the Clinical Trials Regulation EU No.536/2014, Article 90, modifications to the germ line 
are not allowed. It must be clarified what this implies for preclinical studies.  
III Reproductive germline gene editing  
Potentially in the future, depending on the outcomes of basic and preclinical research and taking 
account of societal views, risks and implications (see below), moving towards the clinic may be 
considered. If so, this should be embedded in a formal research trajectory. According to the Clinical 
Trials Regulation EU No.536/2014, Article 90 “No gene therapy clinical trials may be carried out 
which result in modifications to the subject’s germ line genetic identity.” The implication of this 
regulation, is that adequate clinical GLGE research is impossible in the EU. Potentially this would also 
apply to preclinical research. Meanwhile, the clinical applications may take place outside the EU and 
in some cases may be carried out without proper research protocols and oversight. Given the 
technological development and the ethical analysis as described in the background document 
comparing GLGE to other available reproductive options, the time has come to discuss the rationale 
and consequences of the Clinical Trials Regulation. 
If shown to be safe and effective, clinical GLGE may come to have important benefits for prospective 
parents at high risk of having a child affected by a serious genetic disorder and for whom for instance 
preimplantation genetic diagnosis (PGD) is not a real option.  
Categorical deontological objections to clinical GLGE - in terms of being at odds with e.g. naturalness, 
human dignity, or the preservation of the human gene pool as a common heritage – are often used 
both in public debate and legal discourse. While these objections may be relevant for possible 
(mostly rather theoretical) enhancement-like applications of GLGE, they seem unconvincing when it 
comes to possible applications of GLGE with a clear therapeutic or preventive aim, as elaborated in 
the Background document. A better understanding of these objections, and the context in which 
they are used, is needed to inform future policy decisions, public debate and the counseling of 
individual patients.  
Consequentialist objections to reproductive GLGE, regarding both A) health risks and B) societal 
concerns, merit more scrutiny and debate.  
A) Health risks 
In the context of GLGE health risks should be taken to refer to not only those affecting the first 
generation but also possible subsequent ones. Different types of possible adverse effects (off-target 
and pleiotropic, genetic and epigenetic) need investigation. In view of the many unknowns, any use 
of germline gene editing methods for clinical purposes, including any reproductive use of gametes 
derived from edited pluripotent somatic cells, should be regarded as premature and therefore at 
present unacceptable.  
Clinical applications can only become morally justified if adequate pre-clinical safety research, 
including (human) embryo research, shows clinical GLGE to be sufficiently safe and efficient. The 
proper standard for the evaluation of possible residual risks (‘how safe is safe enough in order to 
start clinical applications?’) needs specific assessment after further debate and clarification.  
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If comprehensive PGT of edited embryos on the basis of whole genome sequencing would be 
included as a safeguard in future clinical GLGE, this testing should be focused on possible off-target 
effects, taking into account potential mosaicism.  A possible broadening of the interpretation of the 
raw data generated by such PGT raises complex additional ethical issues and would need further 
multidisciplinary analysis and debate. The proportionality of such broader analysis should not be 
taken for granted, it may generate more questions than answers, as elaborated in the Background 
document.  
Furthermore, any potential future reproductive GLGE would require prospective data collection of 
reproductive outcomes and long-term follow-up studies on the health of children thus conceived. 
Possible practical barriers and limits (in terms of, for example, lack of funding or tensions between 
long term follow up and familial and children’s privacy) may render this challenging, as with long-
term follow-up of children conceived through new reproductive technologies generally. 
  
B) Societal concerns 
The major societal risks often mentioned in this context are inequity, the undermining of 
reproductive autonomy, the position of people affected with impairments or disabilities, and 
possible misuse of GLGE for non-medical applications.  
The disability rights critique forcefully reminds society of its responsibilities towards people with 
disabilities, more particularly its obligation to remove barriers for inclusion, but it should not be used 
as an argument against the development of medical therapies, including GE, irrespective of whether 
it regards somatic or germ-line GE. 
Equal access to health care has to be decided at the level of society as a whole. Public funding, as 
some countries have provided for PGD, can mitigate the concerns regarding inequity. If limited 
funding is available for health care, prioritization is needed. It is conceivable that somatic gene 
editing will be prioritized over GLGE as many serious health problems could be targeted and it might 
be a proportionate (albeit temporary) approach to treatment. The definition and specification of 
seriousness may be a challenge and needs to be assessed within specific national ethical rules and 
regulations.  
Reproductive autonomy should be maintained and respected by both adequate counseling and 
provisions for disabled people. Moreover, while some fear the undermining of reproductive 
autonomy, it should be noted that GLGE may well promote the reproductive autonomy of 
prospective parents at high risk of having a child affected with a serious disorder, as it would increase 
the number of reproductive options (see below). 
In order to ensure strong societal and professional oversight, the experience with regulating PGD and 
other reproductive technologies should help build a sound strategy for regulating possible future 
clinical applications of GLGE, including a licensing system for clinics involved, quality controls and 
obligatory regular reporting by licensed clinics of their handling of requests for GLGE. If clinical GLGE 
would be considered sound, priority should be given to the editing of highly penetrant genes causing 
serious disorders. As the distinction between serious and less serious disorders is unclear, feeding 
fears of a slippery slope, further multidisciplinary reflection on the demarcation of serious disorders 
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is needed. In addition, the distinction between therapy and enhancement is not always clear-cut and 
decisions will need to be made about intermediate subtypes of medical enhancement, such as 
strengthening the human immune system or editing carrier status for recessive disorders or 
structural aberrations. With regard to fears about possible future ‘designer babies’, it is important to 
acknowledge that the prospect of enhancing complex traits (like intelligence) is to a large extent 
science fiction, and that possible efforts to enhance traits would run a disproportional risk of 
antagonistic (harmful) pleiotropic effects. Public debate and education is needed to lower the risk of 
commercial companies seeking to exploit prospective parents’ (unrealistic) preference for a ‘perfect 
child’.  
In view of the medical and societal risks of, and concerns regarding GLGE, it is important to take 
account of other reproductive options for people at high risk of having an affected child. Considering 
the preference of most prospective parents to have a healthy child who is genetically related to both 
of them, PGD aimed at the selective transfer of an unaffected embryo, may be a good ‘preventive’ 
option in most cases. Still, there may be situations where GLGE might be justified, depending upon 
the genetic disorder under consideration, the prospective parents’ genetic makeup, their experiences 
with clinical PGD, their weighing of the possible risks and burdens of a further cycle of IVF/PGD, and 
their moral and religious preferences, including their possible wish to minimize embryo loss. A 
further ethical and societal evaluation of relevant aspects, including the possible health risks of GLGE, 
is needed to define the potential future indications for clinical GLGE as an alternative to PGD that 
aims to selectively transfer an unaffected embryo.  
Possible future routine comprehensive PGT of IVF-embryos using whole genome sequencing, aimed 
at selecting ‘the best embryo’ for transfer, needs proactive scientific, ethical and societal debate. 
Such testing could well, assuming a further improvement of the efficiency of editing (post-zygotic) 
embryos, function as a driver for future routine GLGE, at least among some (wealthy) social groups. 
After all, there will always be potentially pathogenic variants, as all embryos, like humans, are ‘fellow 
mutants’. While this scenario would be problematic in view of the pleiotropic risks of GLGE, it does at 
the same time urge society even more strongly to engage in a more principled debate about the 
ethics of and policymaking regarding the conceptually and morally grey area between therapeutic, 
preventive and enhancement GLGE. 
 
IV Governance 
A process of ongoing public debate about material and procedural ethical and societal issues raised 
by both non-reproductive and reproductive human GLGE is of the utmost importance. Such debate 
should be based on sound scientific evidence as well as sound ethical, legal and social reflection in 
such a manner that many different stakeholders can understand and take part. A strategic plan, 
including the funding, practical and temporal aspects should be devised to ensure that such debates 
are prioritized and undertaken at the same time that the science and policy discussions evolve. Multi-
stakeholder debates should be inclusive; apart from scientists and clinicians, other stakeholders 
should be invited to participate, including patients’ organizations, different lay publics, policymakers, 
and scholars in the medical humanities.  
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These current Recommendations build a first, joint, contribution of both the ESHRE and the ESHG to 
the suggested ongoing trajectory of professional and public deliberations. The Recommendations are 
of a provisional nature and are to be evaluated regularly and systematically to facilitate flexibility in 
approaches and regulation. 
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